Aspen sales leap on GSK, Merck drug buys; Pfizer, Astellas part ways on Lipitor combo in Japan;

@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Perrigo recalls 367,000 tubes of nicotine lozenges. Story | Follow @FiercePharma

@EricPFierce: Cipla is spending $17M to buy two plants from one of its contractors. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI, Our latest special report - The top 10 best-selling MS drugs of 2013 - is here. Report | Follow @CarlyHFierce

> Aspen Pharmacare, Africa's biggest generics maker, saw profits rise as drug buys from GlaxoSmithKline ($GSK) and Merck ($MRK) helped boost international sales. Report

> Pfizer Japan will go it alone on promoting Caduet, a Lipitor/Norvasc combo pill, after canceling its co-marketing arrangement with Astellas. Report

> Sun Pharmaceutical says it's drawing up plans to boost sales of the drugs it will acquire along with Ranbaxy Laboratories in their merger, expected to close later this year. Report

> Pfizer ($PFE) will soon see Viagra competition in China, thanks to Guangzhou Baiyunshan Pharmaceutical's successful bid to win aproval for its knockoff version. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Study: Fecal incontinence implants reduce weekly incontinence episodes in women. Article | Follow @FierceMedDev

@VarunSaxena2: Novel epitope for binding of HIV antibodies has major drug delivery implications. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. Report | Follow @MichaelGFierce

@EmilyWFierce: Physicians find little difference between old and new orthopedic implants, suggest "facts box" for knee & hip devices. MedPage Today article | Follow @EmilyWFierce

> Scientist who discovered BRCA breast cancer gene advocates for systematic screening. More

> Study shows COPD device effective in deterring mucus buildup. Story

Biotech News

@FierceBiotech: FDA panel spurns $ACT's cardio combo, jeopardizing its potential. Story | Follow @FierceBiotech

@JohnCFierce: Xenon pitches Genentech, Teva "extreme genetics" ties as it rolls out a $52M. News | Follow @JohnCFierce

@DamianFierce: $AGN and Ackman have resorted to WWE-level taunts and provocations and it hasn't stopped being entertaining. Article via Reuters | Follow @DamianFierce

@EmilyMFierce: Compound inhibits both MERS, SARS. More | Follow @EmilyMFierce

> R&D pioneer tackles the next hurdle in gene therapy: Paying for $1M-plus drugs. More

> Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice. Article

> Genmab re-ups with Seattle Genetics on a $211M armed antibody cancer drug pact. Story

Drug Delivery News

> Microneedle patch delivers painkiller to second layer of skin in 5 minutes. Report

> Low T products under FDA scrutiny over safety concerns. Item

> Novaliq dissolvable drops improve eye quality in clinical trials. Story

> HIV-fighting intravaginal ring research nets $20M from NIH. More

> Novel epitope for binding of HIV antibodies has major drug delivery implications. Article

Diagnostics News

> Veracyte grabs Allegro Diagnostics for $21M and jumps into lung cancer test space. News

> U.K. test may help Roche's cancer drug Avastin target ideal patients. More

> GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. Report

> ASCO: Provista's autoantibody/biomarker combo boosts breast cancer screening accuracy. Article

> Myriad's multigene predictive cancer test shows utility in new trial. Story

Pharma Marketing News

> Attention market-access experts: NICE won't take pharma's word on cost-effectiveness anymore. Item

> Think a $150K cancer drug is pricey? Try a $1M-plus gene therapy. Editor's corner

> Teva goes analog for asthma with hands-on waiting-room game. Article

> Auxilium's Low-T woes put sales reps in line for layoffs. Story

> Free speech, PhRMA? Not in this off-label marketing case, feds say. More

And Finally... Airline crews had about twice the incidence of melanoma as the general population in a new study. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.